Regulatory peptides from chromogranin A and secretogranin II: Putative modulators of cells and tissues involved in inflammatory conditions

Regulatory Peptides

Volumn 165, Issue 1, 2010, Pages 45-51

  Helle, Karen B ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Catestatin; CgA; Inflammation; Regulatory peptides; Secretoneurin; SgII; Vasostatin I

Indexed keywords

C REACTIVE PROTEIN; CATESTATIN; CD14 ANTIGEN; CHROMOGRANIN A; INTERLEUKIN 16; NEUROPEPTIDE; NITRIC OXIDE; SECRETOGRANIN II; SECRETONEURIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOSTATIN I;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; BIOLOGICAL ACTIVITY; CALCIUM HOMEOSTASIS; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL MOTILITY; CELLULAR DISTRIBUTION; CHEMOTAXIS; DEGENERATIVE DISEASE; ENZYME PHOSPHORYLATION; HEART MUSCLE CONTRACTILITY; HUMAN; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; MAST CELL; MICROGLIA; NONHUMAN; PATHOGENESIS; PEPTIDE ANALYSIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; CHROMOGRANIN A; HUMANS; INFLAMMATION; NEUROPEPTIDES; PEPTIDE FRAGMENTS; SECRETOGRANIN II;

EID: 78649811425     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.09.009     Document Type: Review

References (106)

1. Huttner W.B., Gerdes H.-H., Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci 1991, 16:27-31.
2. Winkler H., Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 1992, 49:497-528.
3. Corti A., Ferrari R., Ceconi C. Chromogranin A and tumor necrosis factor-alpha (TNF) in chronic heart failure. Adv Exp Med Biol 2000, 482:351-359.
4. Ceconi C., Ferrari R., Bachetti T., Opasich C., Volterrani M., Colombo B., Parrinello G., Corti A. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002, 23:967-974.
5. O'Connor D.T., Mahata S.K., Taupenot L., Mahata M., Livsey Taylor C.V., Kailasam M.T., Ziegler M.G., Parmer R.J. Chromogranin A in human disease. Adv Exp Med Biol 2000, 482:377-388.
6. Di Comite G., Marinosci A., Di Matteo P., Manfredi A., Rovere-Querini P., Baldissera E., Aiello P., Corti A., Sabbadini M.G. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis. Ann N Y Acad Sci 2006, 1069:428-437.
7. Di Comite G., Rossi C.M., Marinosci A., Lolmede K., Baldissera E., Aiello P., Mueller R.B., Herrmann M., Voll R.E., Rovere-Querini P., Sabbadini M.G., Corti A., Manfredi A.A. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-{alpha}-elicited endothelial activation. J Leukoc Biol 2009, 85:81-87.
8. Zhang D., Lavaux T., Voegeli A.C., Lavigne T., Castelain V., Meyer N., Sapin R., Aunis D., Metz-Boutigue M.H., Schneider F. Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin Chem 2007, 54:1497-1503.
9. Vaudry H., Conlon J.M. Identification of a peptide arising from the specific post-translation processing of secretogranin II. FEBS Lett 1991, 284:31-33.
10. Kähler C.M., Kaufmann G., Kähler S.T., Wiedermann C.J. The neuropeptide secretoneurin stimulates adhesion of human monocytes to arterial and venous endothelial cells in vitro. Regul Pept 2002, 110:65-73.
11. Kähler C.M., Schratzberger P., Kaufmann G., Hochleitner B., Bechter O., Gøtsch C., Wøll E., Marschang P., Herold M., Wiedermann C.J. Transendothelial migration of leukocytes and signalling mechanisms in response to the neuropeptide secretoneurin. Regul Pept 2002, 105:35-46.
12. Taupenot L., Ciesielski-Treska J., Ulrich G., Chasserot-Golaz S., Aunis D., Bader M.F. Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience 1996, 72:377-389.
13. Ciesielski-Treska J., Aunis D. Chromogranin A induces a neurotoxic phenotype in brain microglial cells. Adv Exp Mol Biol 2000, 482:291-298.
14. Hooper C., Pocock J.M. Chromogranin A activates diverse pathways mediating inducible nitric oxide expression and apoptosis in primary microglia. Neurosci Lett 2007, 413:227-232.
15. Ghia J.E., Crenner F., Metz-Boutigue M.-H., Aunis D., Angel F. The effect of a chromogranin A-derived peptide (CgA4-16) in the writhing nociceptive induced by acetic acids in rats. Life Sci 2004, 75:1787-1799.
16. Ghia J.E., Crenner F., Rohr S., Meyer C., Metz-Boutigue M.-H., Aunis D., Angel F. A role for chromogranin A (4-16), a vasostatin-derived peptide, on human colonic motility. An in vitro study. Regul Pept 2004, 121:31-39.
17. Ghia J.E., Pradaut I., Crenner F., Metz-Boutigue M.-H., Aunis D., Angel F. Effect of acetic acid or trypsin application on rat colonic motility in vitro and modulation by two synthetic fragments of chromogranin A. Regul Pept 2005, 124:27-35.
18. Ferrero E., Scabini S., Magni E., Foglieni C., Belloni D., Colombo B., Curnis F., Villa A., Ferrero M.E., Corti A. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J 2004, 18:554-556.
19. Blois A., Srebro B., Mandalà M., Cort A., Helle K.B., Serck-Hanssen G. The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Regul Pept 2006, 135:78-84.
20. Belloni D., Scabini S., Foglieni C., Veschini L., Giazzon A., Colombo B., Fulgenzi A., Helle K.B., Ferrero M.E., Corti A., Ferrero E. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J 2007, 21:3052-3062.
21. Helle KB. Chromogranins A and B and secretogranin II as prohormones for regulatory peptides from the diffuse neuroendocrine system. In Cellular Peptide Hormone Synthesis and Secretory Pathways (Eds. Rehfeld JF and Bundgaard JR), Springer Press, Heidelberg, Germany, in press.
22. Kennedy B.P., Mahata S.K., O'Connor D.T., Ziegler M.G. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 1998, 19:1241-1248.
23. Kruger P.-G., Mahata S.K., Helle K.B. Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul Pept 2003, 114:29-35.
24. Lugardon K., Raffner R., Goumon Y., Corti A., Delmas A., Bulet P., Aunis D., Metz-Boutigue M.-H. Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 2000, 275:10745-10753.
25. Briolat J., Wu S.D., Mahata S.K., Gonthier B., Bagnard D., Chasserot-Golaz S., Helle K.B., Aunis D., Metz-Boutigue M.-H. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol Life Sci 2005, 62:377-385.
26. Pieroni M., Corti A., Tota B., Curtis F., Angelone T., Colombo B., Cerra M.C. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007, 28:1117-1127.
27. Håkanson R., Ding X.Q., Norlen P., Chen D. Circulating pancreastatin is a marker for the enterochromaffin-like cells of the rat stomach. Gastroenterology 1995, 108:1445-1452.
28. Cubeddu L.X., O'Connor D.T., Parmer R.J. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy. J Clin Oncol 1995, 13:581-587.
29. O'Connor D.T., Cervenka J.H., Stone R.A., Parmer R.J., Franco-Bourland R.E., Madrazo I., Langlais P.J. Chromogranin A immunoreactivity in human cerebrospinal fluid: properties, relationship to noradrenergic neuronal activity and variation in neurological disease. Neuroscience 1993, 56:999-1007.
30. Kirchmair R., Hogue-Angeletti R., Gutierrez J., Fischer-Colbrie R., Winkler H. Secretoneurin - a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C). Neuroscience 1993, 53:359-365.
31. Ischia R., Hobisch A., Bauer R., Weiss U., Gasser R.W., Horninger W., Bartsch G., Fuchs D., Bartch G., Winkler H., Klocker H., Fischer-Colbrie R., Culig Z. Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. J Urol 2000, 163:1161-1165.
32. Børglum T., Rehfeld J.F., Drivsholm L.B., Hilsted L. Processing-independent quantitation of chromogranin A in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas. Clin Chem 2007, 53:438-446.
33. Takiyyuddin M.A., Parmer R.J., Kailasam M.T., Cervenka J.H., Kennedy B., Ziegler M.G., Lin M.C., Li J., Grim C.E., Wright F.A. Chromogranin A in human hypertension. Influence of heredity. Hypertension 1995, 26:213-220.
34. Jansson A.M., Røsjø H., Omland T., Karlsson T., Hartford M., Flyvbjerg A., Caidahi K. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 2009, 36:25-32.
35. Wiedermann C.J. Secretoneurin: a functional neuropeptide in health and disease. Peptides 2000, 21:1289-1298.
36. Kähler C.M., Fischer-Colbrie R. Secretoneurin - a novel link between the nervous and the immune system. Adv Exp Med Biol 2000, 482:279-290.
37. Tatemoto K., Efendic S., Mutt V, Makk G., Feistner G.J., Barchas J.D. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature (Lond) 1986, 324:476-478.
38. Aardal S., Helle K.B., Elsayed S., Reed R.K., Serck-Hanssen G. Vasostatins, comprising the N-terminal domains of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 1993, 5:105-112.
39. Russell J., Gee P., Liu S.M., Angeletti R.H. Stimulation of parathyroid hormone secretion by low calcium is inhibited by amino terminal chromogranin peptides. Endocrinology 1994, 135:337-342.
40. Mahata S.K., O'Connor D.T., Mahata M., Yoo S.H., Taupenot L., Wu H. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997, 100:1623-1633.
41. Saria A., Troger J., Kirchmair R., Fischer-Colbrie R., Hogue-Angeletti R., Winkler H. Secretoneurin releases dopamine from rat striatal slices: a biological effect of a peptide derived from secretogranin II (chromogranin C). Neuroscience 1993, 54:1-4.
42. Helle K.B. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev (Cambr) 2004, 79:769-794.
43. Helle K.B., Corti A., Metz-Boutigue M.-H., Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007, 64:2863-2886.
44. Angeletti R.H., Mints L., Aber C., Russel J. Determination of residues in chromogranin A (16-40) required for inhibition of parathyroid hormone secretion. Endocrinology 1996, 137:2918-2922.
45. Lugardon K., Chasserot-Golaz S., Kieffer A.E., Maget-Dana R., Nullans G., Kieffer B., Aunis D., Metz-Boutigue M.-H. Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide. J Biol Chem 2001, 276:35875-35882.
46. Jean-François F., Khemtémourian L., Odaert B., Castano S., Grélard A., Manigand C., Bathany K., Metz-Boutigue M.-H., Dufourc E.J. Variability in secondary structure of the antimicrobial peptide cateslytin in powder, solution, DPC micelles and at the air-water interface. Eur Biophys J 2007, 36:1019-1027.
47. Biswas N., Vaingankar S.M., Mahata M., Das M., Gayen J.R., Taupenot L., Torpey J.W., O'Connor D.T., Mahata S.K. Proteolytic cleavage of human chromogranin A containing catestatin variants: different processing at catestatin region by plasmin. Endocrinology 2008, 149:749-757.
48. Oulyadi H., Davoust D., Vaudry H. A determination of the solution conformation of secretoneurin, a neuropeptide originating from the processing of secretogranin II, by 1H-NMR and restrained molecular dynamics. Eur J Biochem 1997, 246:665-673.
49. Aardal S., Helle K.B. The vasoinhibitory activity of bovine chromogranin A fragments (vasostatins) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 1992, 41:9-18.
50. Stridsberg M., Angeletti R.H., Helle K.B. Characterization of N-terminal chromogranin A and chromogranin B in mammals by region-specific radioimmunoassays and chromatographic separation methods. J Endocrinol 2000, 165:703-714.
51. Hutton J.C., Nielsen E., Kastern W. The molecular cloning of the chromogranin A-like precursor of beta-granin and pancreastatin from the endocrine pancreas. FEBS Lett 1988, 236:269-274.
52. Glattard E., Angelone T., Strub J.M., Corti A., Aunis D., Tota B., Metz-Boutigue M.-H., Goumon Y. Characterization of natural vasostatin-containing peptides in rat heart. FEBS J 2006, 273:3311-3321.
53. Blois A., Holmsen H., Martino G., Corti A., Metz-Boutigue M.-H., Helle K.B. Interaction of chromogranin A-derived vasostatins and monolayers of phosphatidyl serine, phosphatidyl choline and phosphatidyl ethanolamine. Regul Pept 2006, 134:30-37.
54. Mahapatra N.R. Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Cardiovasc Res 2008, 80:330-339.
55. Montero-Hadjadje M., Vaingankar S., Elias S., Tostivint H., Mahata S.K., Anouar Y. Chromogranins A and B and secretogranin II: evolutionary and functional aspects. Acta Physiol (Oxf) 2008, 192:309-324.
56. Marksteiner J., Saria A., Kirchmair R., Pycha R., Benesch H., Fischer-Colbrie R., Haring C., Maier H., Ransmayr G. Distribution of secretoneurin-like immunoreactivity in comparison with substance P- and enkephalin-like immunoreactivities in various human forebrain regions. Eur J NeuroSci 1993, 5:1573-1585.
57. Fischer-Colbrie R., Laslop A., Kirchmair R. Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Progr Neurobiol 1995, 46:49-70.
58. Schürmann G., Bishop A.E., Facer P., Eder U., Fischer-Colbrie R., Winkler H. Secretoneurin: a new peptide in the human enteric nervous system. Histochem Cell Biol 1995, 104:11-19.
59. Klimaschewski L., Benndorf K., Kirchmair R., Fischer-Colbrie R., Heym C. Secretoneurin-immunoreactivity in nerve terminals opposing identified preganglionic sympathetic neurons in the rat: co-localization with substance P and enkephalin. J Chem Neuroanat 1995, 9:55-63.
60. Ciesielski-Treska J., Ulrich G., Taupenot L., Chasserot-Golaz S., Corti A., Aunis D., Bader M.F. Chromogranin A induces a neurotoxic phenotype in brain microglial cells. J Biol Chem 1998, 273:14339-14346.
61. Ciesielski-Treska J., Ulrich G., Chasserot-Golaz S., Zwiller J., Revel M.O., Aunis D., Bader M.F. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. J Biol Chem 2001, 276:13113-13120.
62. Kingham P.J., Pocock J.M. Microglial apoptosis induced by chromogranin A is mediated by mitochondrial depolarisation and the permeability transition but not by cytochrome c release. J Neurochem 2000, 74:1452-1462.
63. Amato A., Corti A., Serio R., Mule F. Inhibitory influence of chromogranin A N-terminal fragment (vasostatin-I) on the spontaneous contractions of rat proximal colon. Regul Pept 2005, 130:42-47.
64. Jones S., Howl J. Biochemical applications of the receptor-mimetic peptide mastoparan. Curr Prot Pept Sci 2006, 7:501-508.
65. Helle K.B. The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res Aug 18 2009, Electronic publication ahead of print.
66. 2. PLoS ONE Feb 19 2009, 4:e 4501. Electronic publication.
67. Ben-Haim S., Gacinovic S., Israel O. Cardiovascular infection and inflammation. Semin Nucl Med 2009, 39:103-114.
68. Kosmala W., Derzhko R., Przewlocka-Kosmala M., Orda A., Mazurek W. Plasma levels of TNF-alpha, IL-6, and IL-10 and their relationship with left ventricular diastolic function in patients with stable angina pectoris and preserved left ventricular systolic performance. Coron Artery Dis 2008, 19:375-382.
69. Chrysohoou C., Pitsavos C., Barbetseas J., Kotroyiannis I., Brili S., Vasiliadou K., Papadimitriou L., Stefanadis C. Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). Heart Vessels 2009, 24:22-26.
70. Stumpf C., Jukic J., Yilmaz A., Raaz D., Schmieder R.E., Daniel W.G., Garlichs C.D. Elevated VEGF-plasma levels in young patients with mild essential hypertension. Eur J Clin Invest 2009, 39:31-36.
71. Tatasciore A., Zimarino M., Renda G., Zurro M., Soccio M., Prontera C., Emdin M., Flacco M., Schillaci G., De Caterina R. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res 2008, 31:2137-2146.
72. Kim K.I., Lee J.H., Chang H.J., Cho Y.S., Youn T.J., Chung W.Y., Chae I.H., Choi D.J., Park K.U., Kim C.H. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J 2008, 72:293-298.
73. Bautista L.E., Vera L.M., Arenas I.A., Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005, 19:149-154.
74. Watson T., Goon P.K., Lip G.Y. Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in hypertension. Antioxid Redox Signal 2008, 10:1079-1088.
75. Foster W., Shantsila E., Carruthers D., Lip G.Y., Blann A.D. Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction. Rheumatology (Oxford) Jan 19 2009, Electronic publication ahead of print.
76. Povsic T.J., Goldschmidt-Clermont P.J. Endothelial progenitor cells: markers of vascular reparative capacity. Ther Adv Cardiovasc Dis 2008, 2:199-213.
77. Yan S., Wang X., Chai H., Wang H., Yao Q., Chen C. Secretoneurin increases monolayer permeability in human coronary artery endothelial cells. Surgery 2006, 140:243-251.
78. Reinich N., Kirchmair R., Kähler C.M., Hogue-Angeletti R., Fischer-Colbrie R., Winkler H. Attraction of human monocytes by the neuropeptide secretoneurin. FEBS Lett 1993, 334:41-44.
79. Kähler C.M., Kaufmann G., Kähler S.T., Hogue-Angeletti R., Fischer-Colbrie R., Dunzendorfer S., Reinisch N., Wiedermann C.J. A soluble gradient of the neuropeptide secretoneurin promotes the transendothelial migration of monocytes in vitro. Eur J Pharmacol 1999, 365:65-75.
80. Corti A., Mannarino C., Mazza R., Colombo B., Longhi R., Tota B. Vasostatins exert negative inotropism in the working heart of the frog. Ann N Y Acad Sci 2002, 971:362-365.
81. Corti A., Mannarino C., Mazza R., Angelone T., Longi R., Tota B. Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7-57 peptide acts as cardiostatins on the isolating working frog heart. Gen Comp Endocrinol 2004, 136:217-224.
82. Mazza R., Gattuso A., Mannarino C., Brar B.K., Barbieri S.F., Tota B., Mahata S.K. Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am J Physiol Heart Circ Physiol 2008, 295:H113-H1122.
83. Cerra M.C., De Iuri L., Angelone T., Corti A., Tota B. Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res Cardiol 2006, 101:43-52.
84. Cerra M.C., Gallo M.P., Angelone T., Quintieri A.M., Pulerà E., Filice E., Guérold B., Shooshtarizadeh P., Levi R., Ramella R., Brero A., Boero O., Metz-Boutigue M.-H., Tota B., Alloatti G. The homologous rat Chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in the rat heart counteracting the adrenergic stimulation through endothelium-derived nitric oxide mechanisms. FASEB J 2008, 22:3992-4004.
85. Cappello S., Angelone T., Tota B., Pagliaro P., Penna C., Rastaldo R., Corti A., Losano G.A., Cerra M.C. Human recombinant chromogranin A-derived vasostatin1 mimics preconditioning via an adenosine/nitric oxide signalling mechanism. Am J Physiol Heart Circ Physiol 2007, 293:H719-H727.
86. Angelone T., Quintieri A.M., Brar B.K., Limchaiyawet P.T., Tota B., Mahata S.K., Cerra M.C. The antihypertensive chromogranin A peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lucitropism. Endocrinology 2008, 149:4780-4793.
87. Imbrogno S., Angelone T., Corti A., Adamo A., Helle K.B., Tota B. Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen Comp Endocrinol 2004, 139:20-28.
88. Tota B., Mazza R., Angelone T., Nullans G., Metz-Boutigue M.-H., Aunis D., Helle K.B. Peptides from the N-terminal domain of chromogranin A (vasostatins) exert negative inotropic effects in the isolated frog heart. Regul Pept 2003, 114:123-130.
89. Gasparri A., Sidoli A., Sanchez L.P., Longhi R., Siccardi A.G., Marchisio P.C., Corti A. Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain. J Biol Chem 1997, 272:20835-20843.
90. Ratti S., Curnis F., Longhi R., Colombo B., Gasparri A., Magni F., Manera E., Metz-Boutigue M.-H., Corti A. Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J Biol Chem 2000, 275:29257-29263.
91. Egger M., Beer A.G., Theurl M., Schgoer W., Hotter B., Tatrarczyk T., Vasiljevic D., Frauscher S., Marksteiner J., Patsch J.R., Schratzberger P., Djanani A.M., Mahata S.K., Kirchmair R. Monocyte migration: a novel effect and signalling pathways of catestatin. Eur J Pharmacol 2008, 598:104-111.
92. Kähler C.M., Kirschmair R., Kaufmann G., Kähler S.T., Reinisch N., Fischer-Colbrie R., Hogue-Angeletti R., Winkler H., Wiedermann C.J. Inhibition of proliferation and stimulation of migration of endothelial cells by secretoneurin in vitro. Arteroscler Thromb Vasc Biol 1997, 17:932-939.
93. Kähler C.M., Schratzberger P., Wiedermann C.J. Response of vascular smooth muscle cells to the neuropeptide secretoneurin. A functional role for migration and proliferation in vitro. Arteroscler Thromb Vasc Biol 1997, 17:2029-2035.
94. Schratzberger P., Reinish N., Kähler C., Wiedermann C. Deactivation of chemotaxis of human neutrophils by priming with secretogranin II-derived secretoneurin. Regul Pept 1996, 63:65-71.
95. Kong C., Gill B.M., Rahimpour R., Xu L., Feldman R.D., Xiao Q., McDonald T.J., Taupenot L., Mahata S.K., Singh B., O'Connor D.T., Kelvin D.J. Secretoneurin and chemoattractant receptor interactions. J Neuroimmunol 1998, 88:91-98.
96. Kirchmair R., Gander R., Egger M., Walter D.H., Eisterer W., Niederwanger A., Woell E., Nagi M., Pedrini M., Murayama T., Frauscher S., Brochmann M., Sturm W., Fischer-Colbrie R., Losordo D.W., Patch J.R., Schratzberger P. The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo. Circulation 2004, 109:777-783.
97. Kirchmair R., Egger M., Hanley A., Silver M., Ritsch A., Murayama T., Kaneider N., Sturm W., Kearny M., Fischer-Colbrie R., Kirscher B., Gaenzer H., Wiedermann C.J., Ropper A.H., Losordo D.W., Patch J.R., Schratzberger P. Secretoneurin, an angiogenic neuropeptide, induces postnatal vasculogenesis. Circulation 2004, 110:1121-1127.
98. Egger M., Schgoer W., Beer A.G.E., Jeschke J., Leierer J., Theurl M., Frauscher S., Tepper O.M., Niederwanger A., Ritsch A., Kearney M., Wanschitz J., Gurtner G.C., Fischer-Colbrie R., Weiss G., Piza-Katzer H., Losordo D.W., Patch J.R., Schratzberger P., Kirchmair R. Hypoxia up-regulates the angiogenic cytokine secretoneurin via and HIF-1α- and basic FGF-dependent pathway in muscle cells. FASEB J 2007, 21:2906-2917.
99. Fischer-Colbrie R., Kirschmair R., Kaler C.M., Wiedermann C.J., Saria A. Secretoneurin: a new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. Curr Protein Pept Sci 2005, 6:373-385.
100. Shyu W.C., Lin S.Z., Chiang M.F., Chen D.C., Su C.Y., Wang H.J., Liu R.S., Tsai C.H., Li H. Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke. J Clin Invest 2008, 118:133-148.
101. Metz-Boutigue M.-H., Goumon Y., Lugardon K., Strub J.M., Aunis D. Antibacterial peptides are present in chromaffin cell secretory granules. Cell Mol Neurobiol 1998, 18:249-266.
102. Radek K.A., Lopez-Garcia B., Hupe M., Niesman I.R., Elias P.M., Taupenot L., Mahata S.K., O'Connor D.T., Gallo R.L. The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J Invest Dermatol 2009, 128:1525-1534.
103. Angeletti R.H., Aardal S., Serck-Hanssen G., Gee P., Helle K.B. Vasoinhibitory activity of the synthetic peptides from the amino terminus of the adrenomedullary chromogranin A. Acta Physiol Scand 1994, 152:11-19.
104. 125I-secretoneurin analogue to a human monocyte cell line. J Neuroimmunol 1998, 86:87-91.
105. O'Connor D.T., Takiyyuddin M.A., Printz M.P., Dinh T.Q., Barbosa J.A., Rozansky D.J., Mahata S.K., Wu H., Kennedy B.P., Ziegler M.G., Wright F.A., Schlager G., Parmer R.J. Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press 1999, 8:285-295.
106. Colombo B., Longhi R., Marinzi C., Magni F., Cattaneo A., Yoo S.H., Curnis F., Corti A. Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion. J Biol Chem 2002, 277:45911-45919.